Stargardt disease also called Stargardt's macular dystrophy (SMD) that affects approximately one in 10,000 people and described as central vision loss early in life. Stargardt Disease is most commonly caused by mutations in the ABCA4 gene located on chromosome 1 and is inherited in an autosomal recessive manner. This disorder affects the specialized light-sensitive tissue present in the retina. This type of macular degeneration affects the center of the retina which is known as macula which adds sharpness to the central vision. The affected individuals also show the symptoms of color blindness. The signs and symptoms appear in late childhood which is responsible for disease progression.
Market Dynamics
The increasing prevalence of stargardt disease is expected to drive the market growth over the forecast period. For instance, according to the article published in the Association for Research in Vision and Ophthalmology journal, the worldwide prevalence of stargardt disease is estimated to be in between 1 in 8,000 to 10,000 individuals.
Furthermore, key players operating in the Global Stargardt Disease Therapeutics Market are focusing on adoption of growth strategies are expected to drive the market growth during the forecast period. For instance, in July 2017, Ophthotech Corporation, a clinical stage company, is adopting a new strategy to leverage its clinical experience and retina expertise to identify and develop therapies to treat multiple orphan ophthalmic diseases for which there are limited or no treatment options available. Ophthotech’s orphan ophthalmic disease strategy will be led by a randomized, controlled clinical trial assessing the efficacy and safety of Zimura (avacincaptad pegol), the company’s C5 complement inhibitor, for Stargardt disease.
Key features of the study:
- This report provides in-depth analysis of the Global Stargardt Disease Therapeutics Market , and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2023–2028), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the Global Stargardt Disease Therapeutics Market based on the following parameters – Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
- Key companies covered as a part of this study include Kubota Pharmaceutical Holdings Co., Ltd., Stargazer Pharmaceuticals Inc, Iveric Bio, Inc., Sanofi S.A., Alkeus Pharmaceuticals Inc., Astellas Pharma Inc., CHABiotech CO., Ltd., ReVision Therapeutics, Inc., Lin BioScience, Inc., Biogen Inc., F. Hoffmann-La Roche AG.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The Global Stargardt Disease Therapeutics Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Global Stargardt Disease Therapeutics Market .
Detailed Segmentation:
- Global Stargardt Disease Therapeutics Market , By Drug Type:
- Global Stargardt Disease Therapeutics Market , By Age Group:
- Children (Below17 Years)
- Adult (Above 17 Years)
- Global Stargardt Disease Therapeutics Market , By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Stargardt Disease Therapeutics Market , By Region:
- North America
- By Drug Type
- By Age Group
- Children (Below17 Years)
- Adult (Above 17 Years)
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Latin America
- By Drug Type
- By Age Group
- Children (Below17 Years)
- Adult (Above 17 Years)
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Drug Type
- By Age Group
- Children (Below17 Years)
- Adult (Above 17 Years)
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Drug Type
- By Age Group
- Children (Below17 Years)
- Adult (Above 17 Years)
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Drug Type
- By Age Group
- Children (Below17 Years)
- Adult (Above 17 Years)
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Drug Type
- By Age Group
- Children (Below17 Years)
- Adult (Above 17 Years)
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- South Africa
- Central Africa
- North Africa
- Company Profiles
-
- Kubota Pharmaceutical Holdings Co., Ltd.*
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Stargazer Pharmaceuticals Inc.
- Iveric Bio, Inc.
- Sanofi S.A.
- Alkeus Pharmaceuticals Inc.
- Astellas Pharma Inc.
- CHABiotech CO., Ltd
- ReVision Therapeutics, Inc.
- Lin BioScience, Inc.
- Biogen Inc.
- Hoffmann-La Roche AG
“*” marked represents similar segmentation in other categories in the respective section.
